| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Meta is a company that specializes in augmented reality and virtual reality technologies, providing innovative solutions for various industries.
truData Solutions is a modern cloud professional services company, focused on application modernization, innovations and integrations.
Evaxion Biotech is an AI-immunology platform company decoding the immune system to discover and develop immunotherapies for cancer and other diseases.
The Base Technologies, Inc. (BTI) Team won a government contract, in May of 2000, to provide technology solutions to the MHS.